While we have had hits, there were also misses like the use of ATM loss as a predictive biomarker for response in gastric cancer [22], and the availability of a predictive biomarker equivalent to germline/somatic BRCA1/2 mutations that can more consistently or even better predict for tumor responses across a variety of tumor types remains elusive. This evidence concerns the gene BRCA1 and gastric cancer.